Home Alzheimer’s Disease Capivasertib Plus Chemotherapy Leads to Better OS in mCRPC, Despite Missing Trials...

Capivasertib Plus Chemotherapy Leads to Better OS in mCRPC, Despite Missing Trials End Point

Results from the phase 2 ProCAID trial (NCT02121639) indicated that the addition of capivasertib (AZD5363) to chemotherapy resulted in a statistically significant extension in the secondary end point of overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC), reducing the risk of death by 46% versus chemotherapy alone.

did not extend composite progression-free survival (cPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of their PI3K/AKT/PTEN pathway activation status.

However, investigators did observe that the experimental combination did not extend composite progression-free survival (cPFS). Both OS and cPFS results were noted regardless of patient’s PI3K/AKT/PTEN pathway activation status.

These findings, published in the Journal of Clinical Oncology, will require prospective validation studies in order…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Recent Comments